Corcept Therapeutics Inc (CORT)
54.79
-1.66
(-2.94%)
USD |
NASDAQ |
Nov 14, 16:00
54.44
-0.35
(-0.64%)
After-Hours: 20:00
Corcept Therapeutics Gross Profit (Annual): 475.89M for Dec. 31, 2023
Gross Profit (Annual) Chart
Historical Gross Profit (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 475.89M |
| December 31, 2022 | 396.47M |
| December 31, 2021 | 360.70M |
| December 31, 2020 | 348.29M |
| December 31, 2019 | 300.98M |
| December 31, 2018 | 246.03M |
| December 31, 2017 | 155.65M |
| December 31, 2016 | 79.26M |
| December 31, 2015 | 48.92M |
| Date | Value |
|---|---|
| December 31, 2014 | 25.67M |
| December 31, 2013 | 10.21M |
| December 31, 2012 | 3.216M |
| December 31, 2011 | 0.00 |
| December 31, 2010 | 0.00 |
| December 31, 2009 | 0.029M |
| December 31, 2008 | 0.209M |
| December 31, 2007 | 0.482M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (Annual) Range, Past 5 Years
300.98M
Minimum
2019
475.89M
Maximum
2023
376.47M
Average
360.70M
Median
2021
Gross Profit (Annual) Benchmarks
| Catalyst Pharmaceuticals Inc | 346.24M |
| ADMA Biologics Inc | 88.94M |
| Akebia Therapeutics Inc | 120.47M |
| Bioventus Inc | 328.19M |
| Alnylam Pharmaceuticals Inc | 1.518B |